The retail investor response was rubbish.
IMO, they basically acknowledged they are good at focusing on all things medadvisor and its globalisation (without financial forecasts mind you). However, they are terrible at SH management, and subsequently nothing in their management strategies gives consideration of share price.
We’ll just have to wait for revenue to increase before MDR hits the radar of SIs and retail. How long is anyone’s guess based on vaguety expressed this morning.
Add to My Watchlist
What is My Watchlist?
